Class Action Lawsuit Filed Against ImmunityBio, Inc. (NASDAQ: IBRX) by Berger Montague
Berger Montague PC has filed a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX), alleging that the company's Chief Scientific and Medical Officer overstated the performance of its Anktiva platform. The lawsuit claims prior statements about the company's business lacked a reasonable basis, leading to a 21% drop in share price. Investors who purchased shares between January 19, 2026, and March 24, 2026, may seek to be appointed as lead plaintiffs by May 26, 2026.
Tickers: $IBRX
Topics: class action investor losses legal action securities fraud stock price drop